Assembly Bio highlights Phase 2 starts for ABI-6250, GS-1179 in pipeline update

Assembly Biosciences outlined multiple Phase 2 starts across its portfolio in 2026 to early 2027, led by ABI-6250 in liver diseases.

• ABI-6250 Phase 2 in hepatitis D is expected in 4Q 2026, with data expected in 4Q 2027; PBC/PSC Phase 2 is expected in 1Q 2027.
• Gilead-selected HSV candidate GS-1179 targets Phase 2 initiation in recurrent genital herpes in 4Q 2026.
• Cash runway is projected into 2029, supported by a $320.4 million cash position at June 30, 2026.
• The Gilead collaboration extension payment of $75 million is due in 4Q 2026, with additional $75 million payments due in 2028 and 2030.